Therapeutics, Inc.. INTROGEN DNA Sequencing of Viral Gene Therapy Vectors During Pre-Clinical and Clinical Development.

Slides:



Advertisements
Similar presentations
Genetics and Genetic Engineering
Advertisements

Section H Cloning Vectors
Nicolas Hoffmann Pierre Jolicoeur
Mutagenesis Methods Lily Peterson April 5 th, 2010.
Genome Analysis Determine locus & sequence of all the organism’s genes More than 100 genomes have been analysed including humans in the Human Genome Project.
BRMAC Jul-01/Hutchins1 RCA Assays and Clinical Data For a rAd-p53 in Cancer Patients Beth Hutchins, Ph.D. Director, Process Sciences Canji, Inc. (subsidiary.
The Gateway® Cloning System Introduction to the Gateway® System Contents Defining Gateway® technology. Advantages of Gateway® cloning. Ways to enter the.
Chapter 9 Genetics of Bacteria and Their Viruses Jones and Bartlett Publishers © 2005.
Recombinant DNA Technology Site directed mutagenesis Genetics vs. Reverse Genetics Gene expression in bacteria and viruses Gene expression in yeast Genetic.
DNA Technology and Genomics
Genetics and Genetic Engineering terms clones b organisms or cells of nearly identical genetic makeup derived from a single source.
DNA Technology- Cloning, Libraries, and PCR 17 November, 2003 Text Chapter 20.
Presentation on genome sequencing. Genome: the complete set of gene of an organism Genome annotation: the process by which the genes, control sequences.
INTROGEN Absence of RCA Isolated from Patients Treated with INGN 201 (Ad5CMV-p53) Richard Sublett, Ph.D. Director Quality Systems, Introgen Therapeutics.
Ensuring Product Quality in Gene Transfer Clinical Trials
Kristin Rosche, Emily Thornsen & Lloyd Turtinen  Department of Biology  University of Wisconsin-Eau Claire Knockout of the US29 gene of Human Cytomegalovirus.
Trends in Biotechnology
-The methods section of the course covers chapters 21 and 22, not chapters 20 and 21 -Paper discussion on Tuesday - assignment due at the start of class.
Ch5 Sec3 Advances in Genetics. Key Concepts What are three ways of producing organisms with desired traits? What is the goal of the Human Genome Project?
1 Genetics Faculty of Agriculture Instructor: Dr. Jihad Abdallah Topic 13:Recombinant DNA Technology.
Recombinant Technololgy
5.3 – Advances in Genetics Trashketball!. Selecting organisms with desired traits to be parents of the next generation is… A. Inbreeding A. Inbreeding.
PCR provides a forensics tool for identifying colonies
-Know that we can manipulate genomes by inserting or deleting certain genes. -What about synthesizing an entirely novel genome using sequencing technology?
Expression of Deer Adenovirus Spike Protein By: Dang Duong.
Worksheet IX.14 Cloning vehicles - cloning vectors page:
Molecular Biology II Lecture 1 OrR. Restriction Endonuclease (sticky end)
While replication, one strand will form a continuous copy while the other form a series of short “Okazaki” fragments Genetic traits can be transferred.
Molecular Cloning.
Genetic Engineering/ Recombinant DNA Technology
Arabidopsis Thaliana A Study of Genes and Embryo Development By Garen Polatoglu.
MOLECULAR BIOLOGY IN ACTION In this project, students will use what they have learned in the previous courses to complete a larger multi-step molecular.
Plan A Topics? 1.Making a probiotic strain of E.coli that destroys oxalate to help treat kidney stones in collaboration with Dr. Lucent and Dr. VanWert.
Molecular Cloning. Definitions   Cloning :   Obtaining a piece of DNA from its original source (Genome) and introducing it in a DNA vector   Sub-cloning:
Fundamentals of Genetic Engineering. 2 2 What are vectors? Vectors are DNA molecules that act as destination for GOI. Vectors act as a vehicle to ultimately.
Genetic Code and Interrupted Gene Chapter 4. Genetic Code and Interrupted Gene Aala A. Abulfaraj.
2470 bp 1891 bp WT bp 2314 bp A B Fig. S1. Verification with PCR amplification of the.
DNA Technology and Genomics
“How does it affect the protein?”
Gene Mutations.
Volume 88, Issue 5, Pages (March 1997)
Alu insert, PV92 locus, chromosome 16
Cloning Overview DNA can be cloned into bacterial plasmids for research or commercial applications. The recombinant plasmids can be used as a source of.
Figure 7.1 Polymerase chain reaction (PCR).
Vav‐1 gene‐targeting strategy.
Gene Editing Design Demo
Mark M Metzstein, H.Robert Horvitz  Molecular Cell 
Skin-Specific Expression of ank-393, a Novel Ankyrin-3 Splice Variant
LINEs Mobilize SINEs in the Eel through a Shared 3′ Sequence
Recombinant DNA Technology
Rationale for generation of reporter fusions by Red-mediated recombination. Rationale for generation of reporter fusions by Red-mediated recombination.
Expansion of Interstitial Telomeric Sequences in Yeast
Relationship between Genotype and Phenotype
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Volume 88, Issue 5, Pages (March 1997)
High Frequency Retrotransposition in Cultured Mammalian Cells
Objective: Convert a hulled (covered) barley into a hull-less (Naked
Michael A. Rogers, Hermelita Winter, Christian Wolf, Jürgen Schweizer 
Molecular Therapy - Nucleic Acids
APOE Gene Targeting (A) Schematic representation of the endogenous APOE locus, the gene targeting vector and the targeted APOE locus. The exons of the.
Material for Quiz 5 from Chapter 8
Assessing the Functional Characteristics of Synonymous and Nonsynonymous Mutation Candidates by Use of Large DNA Constructs  A.M. Eeds, D. Mortlock, R.
Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii. Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii.
Template Switching by RNA Polymerase II In Vivo
The Gene Mutated in Variant Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN6) and in nclf Mutant Mice Encodes a Novel Predicted Transmembrane Protein 
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
BAC recombineering, gene targeting and RMCE strategies.
Fig. 1. Generation of WNK3 knockout mice
Cloning and mapping of zebrafish nls/raldh2.
Volume 3, Issue 4, Pages (April 2001)
Presentation transcript:

Therapeutics, Inc.

INTROGEN DNA Sequencing of Viral Gene Therapy Vectors During Pre-Clinical and Clinical Development

INTROGEN Forward Looking Statement During the course of this presentation, I may make projections or other forward-looking statements regarding future events. I wish to caution you that such statements are just predictions and that actual events or results may differ materially. Further information on factors that could affect Introgen’s results can be found in the Company’s filings with the Securities and Exchange Commission, including Introgen’s registration statement on Form S-1.

INTROGEN Vector Sequences: Dichotomy Between Belief and Reality Barring sequencing data, the predicted origins and sequence of a vector or plasmid should be considered to be tentative. History of sequencing for RPR/INGN 201 (Ad5CMV-p53 )

INTROGEN Method for Generating Ad5CMV-p53 Shuttle Vector ~7 kb pJM17 ~40 kb 0 pBR322 Ad-L Ad-R Ad-L Ad-R CMV- p53 Ad p53 E4 E2 E3 (E1 del) L

INTROGEN Ad5CMV-p53: Starting Reagents Ad5CMV-p53 and the reagents used to make it originated from the laboratory of Dr. Jack Roth at MDACC. Documentation on the constructs was from academic scientific lab notebooks. Shuttle vector - maps with restriction sites. pJM17 was derived from the Ad5 dl309 adenovirus. Ad5 dl309 was constructed to remove several restriction sites in the Ad5 genome. Ad5 dl309 was selected as a viable virus, and grows as well as wild-type Ad5.

INTROGEN Ad5CMV-p53: Starting Reagents (continued) At this stage we knew the historic building blocks that went into Ad5CMV-p53, and we knew that there had been changes made to several restriction sites in the Ad5 derived part of the Ad5CMV-p53.

INTROGEN Ad5CMV-p53 Sequence, Version 1 Rationale - To confirm the sequence of the expression cassette. Methods - Manual sequencing of expression cassette. Timing - Early in technology transfer from academic laboratory toIntrogen’s research laboratories. Prior to initiation of Phase I trials.

INTROGEN Ad5CMV-p53 Sequence, Version 1 (continued) Conclusions - DNA sequence of expression cassette was as expected. New Information - The polylinker sequences in the expression cassette were now defined.

INTROGEN Ad5CMV-p53 Sequence, Version 1 (continued) Ad-LCMVp53pAAd-R p53 E4 E2 E3 (E1 del) L

INTROGEN Ad5CMV-p53 Sequence p53 E4 E2 E3 In November 1995 Frank Graham and colleagues published a paper regarding changes in E3 region of dl309.

INTROGEN Ad5CMV-p53 Sequence, Version 2 Methods -GLP sequencing of expression cassette cloned out of clinical lot of Ad5CMV- p53, and sequencing of flanking viral DNA sequences directly from Ad5CMV-p53 viral DNA. Timing -Summer of ‘96, Phase I ongoing

INTROGEN Ad5CMV-p53 Sequence, Version 2 (continued) Conclusions - The expression cassette sequence agreed with previous sequence data. New information - –Fully defined sequence of polylinkers between Ad sequences and the expression cassette. –About 300 bp of the left adenoviral flank of Ad5CMV-p53 has more similarity to Ad2 than to Ad5.

INTROGEN Ad5CMV-p53 Sequence In May of ‘98 a paper was published by the group of Estuardo Aguilar-Cordova (Gingras et al) which had a sequence of the E3 insertion/deletion of pJM17 that was slightly different than the sequence of this region of dl309 from the Graham lab. Exact sequence of the E3 insertion/deletion event was unclear.

INTROGEN Ad5CMV-p53 Sequence, Version 3 Method - GLP sequencing of all of Ad5CMV-p53. Rationale - Complete sequence desired prior to initiation of pivotal trials. Timing - April 1999; late Phase II.

INTROGEN Ad5CMV-p53 Sequence, Version 3 (continued) Conclusions p53 expression cassette - No changes. E3 region - Sequence agreed with Gingras et al. Aside from E3 region, there were 23 discrepancies between the predicted sequence, which was based on published data, and the sequence ascertained in this sequencing of Ad5CMV-p53.

INTROGEN Ad5CMV-p53 Sequence, Version 3 (continued) Discrepancies between published (Genbank) sequences and actual sequence found for Ad5CMV-p53 Non-coding/silent10 Amino Acid change 9 Change ORF extent 4

INTROGEN Ad5CMV-p53 Sequence, Version 3 (continued) E3 Region, Ad5CMV-p53, predicted ORFs 12.5K 6.719K11.6K fusionnovel 6 bp delInsertion/deletion E3 Region, wild-type Ad5, predicted ORFs 12.5K 6.719K11.6K10.4K14.5K14.7K

INTROGEN Ad5CMV-p53 Sequence, Version 3 (continued) Predicted changes to E3 proteins of Ad5 vs Ad5CMV-p53.

INTROGEN Ad5CMV-p53 Sequence, Version 3 ( continued ) Nature of sequences inserted into the E3 region : High degree of similarity between a small part of the inserted sequence and a salmon DNA sequence in Genbank (92% over 135 bp). From Gingras et al, we know that DNA from this insert hybridizes to salmon DNA and not human DNA. From studies at Introgen and from Gingras et al we know that RT- PCR detects RNA made from this region. Insertion/Deletion region of E3 (646 base pairs) Novel ORF Homology

INTROGEN Ad5CMV-p53 Sequence p53 E4 E2 E3 (E1 del) L

INTROGEN Conclusions Introgen has sequenced all of Ad5CMV- p53, prior to initiating phase III trials. Until sequencing is completed, there will be uncertainties about the exact identity of almost all plasmids and vectors.

Therapeutics, Inc.